Elevar Therapeutics, a late-stage biopharmaceutical company focused on promising therapies for unmet medical needs in cancer, announced today the initiation of a pivotal trial for the treatment of adenoid cystic cancer (ACC) with the enrollment of the first patient at the University of California, San Francisco Division of Hematology and Oncology.